Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation

Paul M. Cinciripini, David W. Wetter, Cho Lam, Carl De Moor, Lynn Cinciripini, Walter Baile, Janice Y. Tsoh, Cheryl Anderson, John D. Minna

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.

Original languageEnglish (US)
Pages (from-to)282-292
Number of pages11
JournalExperimental and Clinical Psychopharmacology
Volume13
Issue number4
DOIs
StatePublished - Nov 1 2005

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation'. Together they form a unique fingerprint.

  • Cite this

    Cinciripini, P. M., Wetter, D. W., Lam, C., De Moor, C., Cinciripini, L., Baile, W., Tsoh, J. Y., Anderson, C., & Minna, J. D. (2005). Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Experimental and Clinical Psychopharmacology, 13(4), 282-292. https://doi.org/10.1037/1064-1297.13.4.282